JP4819697B2 - 胚体内胚葉 - Google Patents
胚体内胚葉 Download PDFInfo
- Publication number
- JP4819697B2 JP4819697B2 JP2006547496A JP2006547496A JP4819697B2 JP 4819697 B2 JP4819697 B2 JP 4819697B2 JP 2006547496 A JP2006547496 A JP 2006547496A JP 2006547496 A JP2006547496 A JP 2006547496A JP 4819697 B2 JP4819697 B2 JP 4819697B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- definitive endoderm
- human
- sox17
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000001900 endoderm Anatomy 0.000 title description 179
- 210000004027 cell Anatomy 0.000 claims description 451
- 210000004039 endoderm cell Anatomy 0.000 claims description 291
- 101000652324 Homo sapiens Transcription factor SOX-17 Proteins 0.000 claims description 196
- 102100030243 Transcription factor SOX-17 Human genes 0.000 claims description 190
- 238000000034 method Methods 0.000 claims description 129
- 238000004113 cell culture Methods 0.000 claims description 88
- 108010023082 activin A Proteins 0.000 claims description 83
- 210000005260 human cell Anatomy 0.000 claims description 67
- 239000003102 growth factor Substances 0.000 claims description 50
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 38
- 108010059616 Activins Proteins 0.000 claims description 35
- 239000000488 activin Substances 0.000 claims description 35
- 102100026818 Inhibin beta E chain Human genes 0.000 claims description 32
- 210000002966 serum Anatomy 0.000 claims description 29
- 230000001965 increasing effect Effects 0.000 claims description 24
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 22
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 22
- 108010023079 activin B Proteins 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 210000000056 organ Anatomy 0.000 claims description 16
- 238000000338 in vitro Methods 0.000 claims description 12
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 10
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 10
- 210000000472 morula Anatomy 0.000 claims description 8
- 210000001161 mammalian embryo Anatomy 0.000 claims description 6
- 210000002894 multi-fate stem cell Anatomy 0.000 claims description 6
- 210000004392 genitalia Anatomy 0.000 claims description 5
- 210000004602 germ cell Anatomy 0.000 claims description 3
- 238000012606 in vitro cell culture Methods 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 description 236
- 239000003550 marker Substances 0.000 description 148
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 121
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 119
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 103
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 103
- 108090000623 proteins and genes Proteins 0.000 description 87
- 108010079274 Thrombomodulin Proteins 0.000 description 84
- 102000012607 Thrombomodulin Human genes 0.000 description 84
- 230000004069 differentiation Effects 0.000 description 71
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 50
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 50
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 43
- 239000012091 fetal bovine serum Substances 0.000 description 43
- -1 HNF3b Proteins 0.000 description 38
- 238000003753 real-time PCR Methods 0.000 description 34
- 238000011282 treatment Methods 0.000 description 32
- 239000000203 mixture Substances 0.000 description 31
- 230000009278 visceral effect Effects 0.000 description 29
- 102100022716 Atypical chemokine receptor 3 Human genes 0.000 description 25
- 102100033611 CB1 cannabinoid receptor-interacting protein 1 Human genes 0.000 description 25
- 102100038520 Calcitonin receptor Human genes 0.000 description 25
- 102100027570 Forkhead box protein Q1 Human genes 0.000 description 25
- 101000678890 Homo sapiens Atypical chemokine receptor 3 Proteins 0.000 description 25
- 101000945426 Homo sapiens CB1 cannabinoid receptor-interacting protein 1 Proteins 0.000 description 25
- 101000741435 Homo sapiens Calcitonin receptor Proteins 0.000 description 25
- 101000942084 Homo sapiens Cysteine-rich protein 1 Proteins 0.000 description 25
- 101000878124 Homo sapiens Fibroblast growth factor 17 Proteins 0.000 description 25
- 101000861406 Homo sapiens Forkhead box protein Q1 Proteins 0.000 description 25
- 101150045640 VWF gene Proteins 0.000 description 25
- 210000003716 mesoderm Anatomy 0.000 description 25
- 102100036537 von Willebrand factor Human genes 0.000 description 25
- 102100035308 Fibroblast growth factor 17 Human genes 0.000 description 24
- 102100024208 Homeobox protein MIXL1 Human genes 0.000 description 24
- 101001052462 Homo sapiens Homeobox protein MIXL1 Proteins 0.000 description 24
- 210000000130 stem cell Anatomy 0.000 description 23
- 101000819074 Homo sapiens Transcription factor GATA-4 Proteins 0.000 description 22
- 102100021380 Transcription factor GATA-4 Human genes 0.000 description 22
- 210000003981 ectoderm Anatomy 0.000 description 19
- 101100310647 Homo sapiens SOX17 gene Proteins 0.000 description 17
- 101150007417 SOX17 gene Proteins 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 15
- 102100038146 Homeobox protein goosecoid Human genes 0.000 description 14
- 101001032602 Homo sapiens Homeobox protein goosecoid Proteins 0.000 description 14
- 101000976653 Homo sapiens Zinc finger protein ZIC 1 Proteins 0.000 description 14
- 102100023497 Zinc finger protein ZIC 1 Human genes 0.000 description 14
- 230000006698 induction Effects 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 238000010195 expression analysis Methods 0.000 description 13
- 210000002950 fibroblast Anatomy 0.000 description 13
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 12
- 210000001654 germ layer Anatomy 0.000 description 12
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 210000002304 esc Anatomy 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- 238000000926 separation method Methods 0.000 description 11
- 101000844802 Lacticaseibacillus rhamnosus Teichoic acid D-alanyltransferase Proteins 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 238000003365 immunocytochemistry Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 8
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 8
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 210000002257 embryonic structure Anatomy 0.000 description 8
- 102000049228 human SOX17 Human genes 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 210000004153 islets of langerhan Anatomy 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 238000002372 labelling Methods 0.000 description 8
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 7
- 101150066398 CXCR4 gene Proteins 0.000 description 7
- 101000955035 Homo sapiens Homeobox protein MOX-1 Proteins 0.000 description 7
- 101001108219 Homo sapiens NADPH oxidase 1 Proteins 0.000 description 7
- 101001098352 Homo sapiens OX-2 membrane glycoprotein Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 210000002242 embryoid body Anatomy 0.000 description 7
- 230000007045 gastrulation Effects 0.000 description 7
- 210000000936 intestine Anatomy 0.000 description 7
- 108010012236 Chemokines Proteins 0.000 description 6
- 102000019034 Chemokines Human genes 0.000 description 6
- 102100037099 Homeobox protein MOX-1 Human genes 0.000 description 6
- 102100041030 Pancreas/duodenum homeobox protein 1 Human genes 0.000 description 6
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 description 6
- 238000002659 cell therapy Methods 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000001936 parietal effect Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 102000000844 Cell Surface Receptors Human genes 0.000 description 5
- 108010001857 Cell Surface Receptors Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 108700039887 Essential Genes Proteins 0.000 description 5
- 101150055123 afp gene Proteins 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000010606 normalization Methods 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 4
- 102000005606 Activins Human genes 0.000 description 4
- 108050006400 Cyclin Proteins 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102000043168 TGF-beta family Human genes 0.000 description 4
- 108091085018 TGF-beta family Proteins 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 229930002330 retinoic acid Natural products 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 229960001727 tretinoin Drugs 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 102000000905 Cadherin Human genes 0.000 description 3
- 108050007957 Cadherin Proteins 0.000 description 3
- 102000009410 Chemokine receptor Human genes 0.000 description 3
- 108050000299 Chemokine receptor Proteins 0.000 description 3
- 239000012979 RPMI medium Substances 0.000 description 3
- 102000013814 Wnt Human genes 0.000 description 3
- 108050003627 Wnt Proteins 0.000 description 3
- 239000007801 affinity label Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000000394 mitotic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 108010061299 CXCR4 Receptors Proteins 0.000 description 2
- 102000012000 CXCR4 Receptors Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 2
- 101000652332 Homo sapiens Transcription factor SOX-1 Proteins 0.000 description 2
- 101000652326 Homo sapiens Transcription factor SOX-18 Proteins 0.000 description 2
- 101000642523 Homo sapiens Transcription factor SOX-7 Proteins 0.000 description 2
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000008730 Nestin Human genes 0.000 description 2
- 108010088225 Nestin Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102100034850 Peptidyl-prolyl cis-trans isomerase G Human genes 0.000 description 2
- 101710111200 Peptidyl-prolyl cis-trans isomerase G Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 101150036757 SPARC gene Proteins 0.000 description 2
- 102000006467 TATA-Box Binding Protein Human genes 0.000 description 2
- 108010044281 TATA-Box Binding Protein Proteins 0.000 description 2
- 102100030248 Transcription factor SOX-1 Human genes 0.000 description 2
- 102100030249 Transcription factor SOX-18 Human genes 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 102000052241 human SOX7 Human genes 0.000 description 2
- 238000012760 immunocytochemical staining Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 210000005055 nestin Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000001811 primitive streak Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000013515 script Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102100030012 Deoxyribonuclease-1 Human genes 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 241000531123 GB virus C Species 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 102100029284 Hepatocyte nuclear factor 3-beta Human genes 0.000 description 1
- 101001062347 Homo sapiens Hepatocyte nuclear factor 3-beta Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 description 1
- 101000772267 Homo sapiens Thyrotropin receptor Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 101150042431 SOX gene Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 101100184148 Xenopus laevis mix-a gene Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000010201 enrichment analysis Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 102000051206 human THBD Human genes 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000012309 immunohistochemistry technique Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000010311 mammalian development Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000011880 melting curve analysis Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 108700005467 recombinant KCB-1 Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0679—Cells of the gastro-intestinal tract
- C12N5/068—Stem cells; Progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53200403P | 2003-12-23 | 2003-12-23 | |
| US60/532,004 | 2003-12-23 | ||
| US58656604P | 2004-07-09 | 2004-07-09 | |
| US60/586,566 | 2004-07-09 | ||
| US58794204P | 2004-07-14 | 2004-07-14 | |
| US60/587,942 | 2004-07-14 | ||
| PCT/US2004/043696 WO2005063971A2 (en) | 2003-12-23 | 2004-12-23 | Definitive endoderm |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011168363A Division JP5669688B2 (ja) | 2003-12-23 | 2011-08-01 | 胚体内胚葉 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007516728A JP2007516728A (ja) | 2007-06-28 |
| JP2007516728A5 JP2007516728A5 (enExample) | 2010-08-12 |
| JP4819697B2 true JP4819697B2 (ja) | 2011-11-24 |
Family
ID=34743694
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006547496A Expired - Lifetime JP4819697B2 (ja) | 2003-12-23 | 2004-12-23 | 胚体内胚葉 |
| JP2011168363A Expired - Lifetime JP5669688B2 (ja) | 2003-12-23 | 2011-08-01 | 胚体内胚葉 |
| JP2014186172A Expired - Lifetime JP6356021B2 (ja) | 2003-12-23 | 2014-09-12 | 胚体内胚葉 |
| JP2015111659A Pending JP2015163081A (ja) | 2003-12-23 | 2015-06-01 | 胚体内胚葉 |
| JP2016232292A Expired - Lifetime JP6574158B2 (ja) | 2003-12-23 | 2016-11-30 | 胚体内胚葉 |
| JP2018130280A Pending JP2018171071A (ja) | 2003-12-23 | 2018-07-09 | 胚体内胚葉 |
| JP2020032178A Expired - Lifetime JP7045407B2 (ja) | 2003-12-23 | 2020-02-27 | 胚体内胚葉 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011168363A Expired - Lifetime JP5669688B2 (ja) | 2003-12-23 | 2011-08-01 | 胚体内胚葉 |
| JP2014186172A Expired - Lifetime JP6356021B2 (ja) | 2003-12-23 | 2014-09-12 | 胚体内胚葉 |
| JP2015111659A Pending JP2015163081A (ja) | 2003-12-23 | 2015-06-01 | 胚体内胚葉 |
| JP2016232292A Expired - Lifetime JP6574158B2 (ja) | 2003-12-23 | 2016-11-30 | 胚体内胚葉 |
| JP2018130280A Pending JP2018171071A (ja) | 2003-12-23 | 2018-07-09 | 胚体内胚葉 |
| JP2020032178A Expired - Lifetime JP7045407B2 (ja) | 2003-12-23 | 2020-02-27 | 胚体内胚葉 |
Country Status (15)
| Country | Link |
|---|---|
| US (8) | US7704738B2 (enExample) |
| EP (2) | EP1709159B1 (enExample) |
| JP (7) | JP4819697B2 (enExample) |
| KR (1) | KR101221302B1 (enExample) |
| CN (2) | CN103898045B (enExample) |
| AU (2) | AU2004309421B2 (enExample) |
| CA (2) | CA2807342C (enExample) |
| DK (2) | DK1709159T3 (enExample) |
| EA (1) | EA200601231A1 (enExample) |
| HK (3) | HK1197082A1 (enExample) |
| IL (1) | IL176336A (enExample) |
| MX (2) | MX2009009225A (enExample) |
| NZ (1) | NZ547920A (enExample) |
| SG (1) | SG149061A1 (enExample) |
| WO (1) | WO2005063971A2 (enExample) |
Families Citing this family (149)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7432104B2 (en) * | 2001-08-06 | 2008-10-07 | Bresgen Inc. | Methods for the culture of human embryonic stem cells on human feeder cells |
| GB2399823B (en) * | 2001-12-07 | 2006-02-15 | Geron Corp | Islet cells from primate pluripotent stem cells |
| US20060003446A1 (en) * | 2002-05-17 | 2006-01-05 | Gordon Keller | Mesoderm and definitive endoderm cell populations |
| WO2004098490A2 (en) | 2002-05-17 | 2004-11-18 | Mount Sinai School Of Medicine Of New York University | Mesoderm and definitive endoderm cell populations |
| WO2007059007A2 (en) * | 2005-11-14 | 2007-05-24 | Cythera, Inc. | Markers of definitive endoderm |
| US20050266554A1 (en) * | 2004-04-27 | 2005-12-01 | D Amour Kevin A | PDX1 expressing endoderm |
| US8647873B2 (en) | 2004-04-27 | 2014-02-11 | Viacyte, Inc. | PDX1 expressing endoderm |
| KR101221302B1 (ko) | 2003-12-23 | 2013-01-11 | 비아싸이트, 인크. | 완전 내배엽 |
| US7625753B2 (en) | 2003-12-23 | 2009-12-01 | Cythera, Inc. | Expansion of definitive endoderm cells |
| US7985585B2 (en) | 2004-07-09 | 2011-07-26 | Viacyte, Inc. | Preprimitive streak and mesendoderm cells |
| US7541185B2 (en) | 2003-12-23 | 2009-06-02 | Cythera, Inc. | Methods for identifying factors for differentiating definitive endoderm |
| EP2377922B1 (en) * | 2004-04-27 | 2020-04-08 | Viacyte, Inc. | PDX1 expressing endoderm |
| WO2006025937A2 (en) * | 2004-07-07 | 2006-03-09 | The University Of North Carolina At Chapel Hill | Embryonic stem cell derivatives, and methods of making and using the same |
| ES2754038T3 (es) * | 2004-07-09 | 2020-04-15 | Viacyte Inc | Células mesendodérmicas y células de línea pre-primitiva |
| EP1791952A4 (en) * | 2004-08-13 | 2008-06-11 | Univ Georgia Res Found | COMPOSITIONS AND METHODS OF SELF-RENEWAL AND DIFFERENTIATION IN HUMAN EMBRYONAL STEM CELLS |
| EP1799810A2 (en) | 2004-10-12 | 2007-06-27 | Technion Research & Development Foundation Ltd. | Isolated primate embryonic cells and methods of generating and using same |
| US8017395B2 (en) | 2004-12-17 | 2011-09-13 | Lifescan, Inc. | Seeding cells on porous supports |
| SG158171A1 (en) * | 2004-12-23 | 2010-01-29 | Cythera Inc | Expansion of definitive endoderm cells |
| AU2005322007B2 (en) * | 2004-12-23 | 2011-06-30 | Viacyte, Inc. | Expansion of definitive endoderm cells |
| JP2008528038A (ja) * | 2005-01-31 | 2008-07-31 | エス セル インターナショナル ピーティーイー リミテッド | 胚性幹細胞の指示された分化及びその利用 |
| US7642091B2 (en) | 2005-02-24 | 2010-01-05 | Jau-Nan Lee | Human trophoblast stem cells and use thereof |
| CA2613889A1 (en) | 2005-06-08 | 2006-12-14 | Centocor, Inc. | A cellular therapy for ocular degeneration |
| CA2626152A1 (en) * | 2005-10-24 | 2007-05-03 | Agency For Science, Technology And Research | Methods of specifying mesodermal, endodermal and mesoendodermal cell fates |
| EP3584311A1 (en) * | 2005-10-27 | 2019-12-25 | Viacyte, Inc. | Pdx-1 expressing dorsal and ventral foregut endoderm |
| JP4463189B2 (ja) | 2005-11-22 | 2010-05-12 | Nec東芝スペースシステム株式会社 | 探索機能付きモバイル装置 |
| EP1994141B1 (en) | 2006-02-23 | 2017-11-15 | ViaCyte, Inc. | Compositions and methods useful for culturing differentiable cells |
| US7695965B2 (en) * | 2006-03-02 | 2010-04-13 | Cythera, Inc. | Methods of producing pancreatic hormones |
| CA2644468C (en) * | 2006-03-02 | 2022-02-01 | Cythera, Inc. | Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production |
| US11254916B2 (en) | 2006-03-02 | 2022-02-22 | Viacyte, Inc. | Methods of making and using PDX1-positive pancreatic endoderm cells |
| GB0615327D0 (en) * | 2006-03-30 | 2006-09-13 | Univ Edinburgh | Culture medium containing kinase inhibitors and uses thereof |
| US7989204B2 (en) * | 2006-04-28 | 2011-08-02 | Viacyte, Inc. | Hepatocyte lineage cells |
| US8741643B2 (en) | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
| EP2027258A2 (en) * | 2006-05-02 | 2009-02-25 | Wisconsin Alumni Research Foundation | Method of differentiating stem cells into cells of the endoderm and pancreatic lineage |
| US8685730B2 (en) | 2006-05-02 | 2014-04-01 | Wisconsin Alumni Research Foundation | Methods and devices for differentiating pluripotent stem cells into cells of the pancreatic lineage |
| CA2654196A1 (en) * | 2006-06-02 | 2007-12-13 | University Of Georgia Research Foundation, Inc. | Pancreatic and liver endoderm cells and tissue by differentiation of definitive endoderm cells obtained from human embryonic stems |
| US8415153B2 (en) | 2006-06-19 | 2013-04-09 | Geron Corporation | Differentiation and enrichment of islet-like cells from human pluripotent stem cells |
| US8874380B2 (en) | 2010-12-09 | 2014-10-28 | Rutgers, The State University Of New Jersey | Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs |
| AU2007277364B2 (en) | 2006-07-26 | 2010-08-12 | Viacyte, Inc. | Methods of producing pancreatic hormones |
| US20100323442A1 (en) * | 2006-10-17 | 2010-12-23 | Emmanuel Edward Baetge | Modulation of the phosphatidylinositol-3-kinase pathway in the differentiation of human embryonic stem cells |
| US9080145B2 (en) | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
| SG183067A1 (en) | 2007-07-20 | 2012-08-30 | Cellartis Ab | A novel population of hepatocytes derived via definitive endoderm (de-hep) from human blastocysts derived stem cells |
| CA3114827C (en) | 2007-07-31 | 2023-09-05 | Lifescan, Inc. | Differentiation of human embryonic stem cells to pancreatic endocrine |
| US7695963B2 (en) | 2007-09-24 | 2010-04-13 | Cythera, Inc. | Methods for increasing definitive endoderm production |
| CA2954431C (en) | 2007-11-27 | 2021-08-24 | Lifescan, Inc. | Differentiation of human embryonic stem cells to pancreatic cells |
| EP2227487A1 (en) | 2007-12-28 | 2010-09-15 | Novo Nordisk A/S | Ddr1-mediated cell purification of pancreatic endocrine cells through their progenitors |
| RU2551772C2 (ru) | 2008-02-21 | 2015-05-27 | Сентокор Орто Байотек Инк. | Способы, поверхностно-модифицированные носители и композиции для иммобилизации, культивирования и открепления клеток |
| JP2011518547A (ja) | 2008-04-03 | 2011-06-30 | ノボ・ノルデイスク・エー/エス | 膵臓内分泌プレ前駆体細胞及びその子孫のdner媒介細胞精製 |
| US8338170B2 (en) | 2008-04-21 | 2012-12-25 | Viacyte, Inc. | Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells |
| EP2283117B1 (en) | 2008-04-21 | 2013-10-23 | Viacyte, Inc. | Methods for purifying pancreatic endoderm cells derived from human embryonic stem cells |
| US7939322B2 (en) * | 2008-04-24 | 2011-05-10 | Centocor Ortho Biotech Inc. | Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm |
| US8623648B2 (en) * | 2008-04-24 | 2014-01-07 | Janssen Biotech, Inc. | Treatment of pluripotent cells |
| WO2009154606A1 (en) | 2008-06-03 | 2009-12-23 | Cythera, Inc. | Growth factors for production of definitive endoderm |
| US20090298178A1 (en) * | 2008-06-03 | 2009-12-03 | D Amour Kevin Allen | Growth factors for production of definitive endoderm |
| MX2011000123A (es) * | 2008-06-30 | 2011-02-25 | Centocor Ortho Biotech Inc | Diferenciacion de las celulas madre pluripotentes. |
| AU2009267137A1 (en) | 2008-06-30 | 2010-01-07 | Centocor Ortho Biotech Inc. | Differentiation of pluripotent stem cells |
| MX2011004563A (es) * | 2008-10-31 | 2011-06-01 | Centocor Ortho Biotech Inc | Diferenciacion de celulas madre embrionarias humanas al linaje endocrino pancreatico. |
| MX2011004565A (es) | 2008-10-31 | 2011-07-28 | Centocor Ortho Biotech Inc | Diferenciacion de celulas madre embrionarias humanas al linaje endocrino pancreatico. |
| US8895300B2 (en) | 2008-11-04 | 2014-11-25 | Viacyte, Inc. | Scalable primate pluripotent stem cell aggregate suspension culture and differentiation thereof |
| DK2356213T3 (da) | 2008-11-04 | 2019-09-09 | Viacyte Inc | Stamcelleaggregatsuspensionssammensætninger og fremgangsmåder til differentiering deraf |
| US8008075B2 (en) | 2008-11-04 | 2011-08-30 | Viacyte, Inc. | Stem cell aggregate suspension compositions and methods of differentiation thereof |
| EP3363444B1 (en) | 2008-11-14 | 2022-09-14 | ViaCyte, Inc. | Encapsulation of pancreatic cells derived from human pluripotent stem cells |
| EP3260534A1 (en) | 2008-11-20 | 2017-12-27 | Janssen Biotech, Inc. | Pluripotent stem cell culture on micro-carriers |
| BRPI0921996A2 (pt) | 2008-11-20 | 2015-08-18 | Centocor Ortho Biotech Inc | Métodos e composições para cultura e ligação de células em substratos planos. |
| EP2367931B1 (en) * | 2008-12-03 | 2017-05-31 | International Stem Cell Corporation | Methods of deriving differentiated cells from stem cells |
| US8507274B2 (en) | 2009-02-06 | 2013-08-13 | President And Fellows Of Harvard College | Compositions and methods for promoting the generation of definitive endoderm |
| EP2233566A1 (en) | 2009-03-17 | 2010-09-29 | Vrije Universiteit Brussel | Generation of pancreatic progenitor cells |
| US9109245B2 (en) | 2009-04-22 | 2015-08-18 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
| WO2010124142A2 (en) | 2009-04-22 | 2010-10-28 | Cythera, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
| EP2435471A2 (en) * | 2009-05-29 | 2012-04-04 | Novo Nordisk A/S | INDUCED DERIVATION OF SPECIFIC ENDODERM FROM hPS CELL-DERIVED DEFINITIVE ENDODERM |
| GB0911060D0 (en) | 2009-06-26 | 2009-08-12 | Ge Healthcare Uk Ltd | Methods for predicting the toxicity of a chemical |
| KR101786735B1 (ko) | 2009-07-20 | 2017-10-18 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 분화 |
| KR101785626B1 (ko) | 2009-07-20 | 2017-10-16 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 분화 |
| EP2456862A4 (en) | 2009-07-20 | 2013-02-27 | Janssen Biotech Inc | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS |
| MX350966B (es) * | 2009-10-29 | 2017-09-26 | Janssen Biotech Inc | Celulas madre pluripotentes. |
| BR112012017761A2 (pt) | 2009-12-23 | 2015-09-15 | Centocor Ortho Biotech Inc | diferenciação das células-tronco embrionárias humanas |
| PH12012501254A1 (en) * | 2009-12-23 | 2012-11-05 | Janssen Biotech Inc | Differentiation of human embryonic stem cells |
| WO2011100291A1 (en) * | 2010-02-09 | 2011-08-18 | The Regents Of The University Of California | Method for identifying pancreatic progenitor cells |
| US9969981B2 (en) | 2010-03-01 | 2018-05-15 | Janssen Biotech, Inc. | Methods for purifying cells derived from pluripotent stem cells |
| US20120100110A1 (en) * | 2010-04-20 | 2012-04-26 | International Stem Cell Corporation | Physiological methods for isolation of high purity cell populations |
| US9719068B2 (en) | 2010-05-06 | 2017-08-01 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| RU2663339C1 (ru) | 2010-05-12 | 2018-08-03 | Янссен Байотек, Инк. | Дифференцирование эмбриональных стволовых клеток человека |
| CA2809300A1 (en) * | 2010-08-31 | 2012-03-08 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| JP6133776B2 (ja) | 2010-08-31 | 2017-05-24 | ヤンセン バイオテツク,インコーポレーテツド | 多能性幹細胞の分化 |
| KR101836850B1 (ko) | 2010-08-31 | 2018-03-09 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 분화 |
| KR20130101557A (ko) | 2010-11-02 | 2013-09-13 | 고꾸리쯔다이가꾸호오진 구마모또 다이가꾸 | 장세포의 제조 방법 |
| GB2502704B (en) | 2010-11-15 | 2019-12-04 | Accelerated Biosciences Corp | Generation of neural stem cells from human trophoblast stem cells |
| WO2012115619A1 (en) | 2011-02-21 | 2012-08-30 | Viacyte, Inc. | Loading system for an encapsulation device |
| ES2902650T3 (es) | 2011-06-21 | 2022-03-29 | Novo Nordisk As | Inducción eficiente de endodermo definitivo a partir de células madre pluripotentes |
| AU2012355698B2 (en) | 2011-12-22 | 2018-11-29 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells into single hormonal insulin positive cells |
| RU2018128383A (ru) | 2012-03-07 | 2019-03-14 | Янссен Байотек, Инк. | Среда определенного состава для размножения и обновления плюрипотентных стволовых клеток |
| AR090970A1 (es) | 2012-05-07 | 2014-12-17 | Janssen Biotech Inc | Diferenciacion de celulas madre humanas embrionarias en endodermo pancreatico |
| US20150140661A1 (en) | 2012-05-25 | 2015-05-21 | Saitama Medical University | Method for producing pancreatic hormone-producing cell, pancreatic hormone-producing cell, and differentiation/induction promoter |
| RU2018108850A (ru) | 2012-06-08 | 2019-02-26 | Янссен Байотек, Инк. | Дифференцировка эмбриональных стволовых клеток человека в панкреатические эндокринные клетки |
| CN104995294A (zh) * | 2012-10-19 | 2015-10-21 | 新加坡科技研究局 | 使干细胞分化成一种或多种细胞谱系的方法 |
| AU2013248265B2 (en) | 2012-11-08 | 2018-11-01 | Viacyte, Inc. | Scalable primate pluripotent stem cell aggregate suspension culture and differentiation thereof |
| CN105102611B (zh) | 2012-11-30 | 2021-09-10 | 艾克塞利瑞提德生物技术公司 | 通过调节mir-124分化干细胞的方法 |
| SG10201707811XA (en) | 2012-12-31 | 2017-11-29 | Janssen Biotech Inc | Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators |
| US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
| EP4039798A1 (en) | 2012-12-31 | 2022-08-10 | Janssen Biotech, Inc. | Suspension and clustering of human pluripotent cells |
| MX2015008577A (es) | 2012-12-31 | 2015-09-07 | Janssen Biotech Inc | Cultivo de celulas madre embrionarias humanas en la interfase aire-liquido para la diferenciacion en celulas endocrinas pancreaticas. |
| US9850465B2 (en) | 2013-02-27 | 2017-12-26 | The Regents Of The University Of California | Generation of thymic epithelial progenitor cells in vitro |
| PL2964147T3 (pl) | 2013-03-07 | 2018-10-31 | Viacyte, Inc. | Trójwymiarowy zestaw urządzeń o dużej pojemności do kapsułkowania komórek |
| USD720469S1 (en) | 2013-03-07 | 2014-12-30 | Viacyte, Inc. | Cell encapsulation device |
| US8859286B2 (en) | 2013-03-14 | 2014-10-14 | Viacyte, Inc. | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells |
| US10266807B2 (en) | 2013-04-03 | 2019-04-23 | FUJIFILM Cellular Dynamics, Inc. | Methods and compositions for culturing endoderm progenitor cells in suspension |
| EP2988699B1 (en) | 2013-04-24 | 2020-05-27 | Société des Produits Nestlé S.A. | Encapsulation device |
| US9856304B2 (en) | 2013-05-24 | 2018-01-02 | Saitama Medical University | Peptide and application thereof |
| KR102423106B1 (ko) | 2013-06-11 | 2022-07-21 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | SC-β 세포 및 조성물 그리고 그 생성 방법 |
| US11051900B2 (en) | 2014-04-16 | 2021-07-06 | Viacyte, Inc. | Tools and instruments for use with implantable encapsulation devices |
| KR102162138B1 (ko) | 2014-05-16 | 2020-10-06 | 얀센 바이오테크 인코포레이티드 | 췌장 내분비 세포에서 mafa 발현을 향상시키기 위한 소분자의 용도 |
| EP3149156B1 (en) | 2014-05-28 | 2021-02-17 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
| JP6804438B2 (ja) | 2014-10-17 | 2020-12-23 | チルドレンズ ホスピタル メディカル センター | 多能性幹細胞を使用するヒト小腸のin vivoモデル、並びにそれを作製、及び使用する方法 |
| SG11201704291QA (en) | 2014-11-26 | 2017-06-29 | Accelerated Biosciences Corp | Induced hepatocytes and uses thereof |
| WO2016100930A1 (en) | 2014-12-18 | 2016-06-23 | President And Fellows Of Harvard College | Methods for generating stem cell-derived b cells and methods of use thereof |
| WO2016100909A1 (en) | 2014-12-18 | 2016-06-23 | President And Fellows Of Harvard College | METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF |
| WO2016100898A1 (en) | 2014-12-18 | 2016-06-23 | President And Fellows Of Harvard College | Serum-free in vitro directed differentiation protocol for generating stem cell-derived b cells and uses thereof |
| SG11201704961VA (en) | 2014-12-19 | 2017-07-28 | Janssen Biotech Inc | Suspension culturing of pluripotent stem cells |
| US10494608B2 (en) | 2015-04-24 | 2019-12-03 | University Of Copenhagen | Isolation of bona fide pancreatic progenitor cells |
| MA45479A (fr) | 2016-04-14 | 2019-02-20 | Janssen Biotech Inc | Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen |
| EP4177335A1 (en) | 2016-05-05 | 2023-05-10 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
| MA45502A (fr) | 2016-06-21 | 2019-04-24 | Janssen Biotech Inc | Génération de cellules bêta fonctionnelles dérivées de cellules souches pluripotentes humaines ayant une respiration mitochondriale glucose-dépendante et une réponse en sécrétion d'insuline en deux phases |
| EP3534976A4 (en) | 2016-11-04 | 2020-09-16 | Children's Hospital Medical Center | PATHOLOGICAL MODELS OF HEPATIC ORGANOIDS AND ASSOCIATED METHODS OF MANUFACTURE AND USE |
| JP7088564B2 (ja) | 2016-11-10 | 2022-06-21 | ヴィアサイト,インコーポレイテッド | 細胞送達装置におけるpdx1膵臓内胚葉細胞及びその方法 |
| EP3548507A4 (en) | 2016-12-05 | 2020-07-15 | Children's Hospital Medical Center | COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF |
| JP6485883B2 (ja) * | 2017-03-01 | 2019-03-20 | 株式会社大一商会 | 遊技機 |
| EP3609997A4 (en) | 2017-04-14 | 2021-03-03 | Children's Hospital Medical Center | COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES |
| CA3066055A1 (en) | 2017-06-14 | 2018-12-20 | Semma Therapeutics, Inc. | Devices and methods for delivering therapeutics |
| US10391156B2 (en) | 2017-07-12 | 2019-08-27 | Viacyte, Inc. | University donor cells and related methods |
| EP3694603A4 (en) * | 2017-10-10 | 2021-07-14 | Children's Hospital Medical Center | ESOPHAGUS TISSUE AND / OR ORGANOID COMPOSITIONS AND METHOD FOR MANUFACTURING THEREOF |
| CA2983845C (en) | 2017-10-26 | 2024-01-30 | University Of Copenhagen | Generation of glucose-responsive beta cells |
| AU2018370029B2 (en) | 2017-11-15 | 2024-11-07 | Vertex Pharmaceuticals Incorporated | Islet cell manufacturing compositions and methods of use |
| US12379372B2 (en) | 2017-12-21 | 2025-08-05 | Children's Hospital Medical Center | Digitalized human organoids and methods of using same |
| KR102887406B1 (ko) | 2018-07-26 | 2025-11-19 | 칠드런즈 호스피탈 메디칼 센터 | 간-담도-췌장 조직 및 이를 제조하는 방법 |
| EP3833365A4 (en) | 2018-08-10 | 2022-05-11 | Vertex Pharmaceuticals Incorporated | Stem cell derived islet differentiation |
| US10724052B2 (en) | 2018-09-07 | 2020-07-28 | Crispr Therapeutics Ag | Universal donor cells |
| WO2020056158A1 (en) | 2018-09-12 | 2020-03-19 | Children's Hospital Medical Center | Organoid compositions for the production of hematopoietic stem cells and derivatives thereof |
| CN114585373B (zh) | 2019-05-06 | 2025-07-22 | 艾克塞利瑞提德生物技术公司 | 前体调节性细胞滋养层细胞及其用途 |
| EP3975926A1 (en) | 2019-05-31 | 2022-04-06 | W.L. Gore & Associates, Inc. | A biocompatible membrane composite |
| EP3976237A1 (en) | 2019-05-31 | 2022-04-06 | W.L. Gore & Associates Inc. | Cell encapsulation devices with controlled oxygen diffusion distances |
| CA3139591C (en) | 2019-05-31 | 2024-01-16 | Timothy M. BRUHN | A biocompatible membrane composite |
| AU2020283056B2 (en) | 2019-05-31 | 2023-06-08 | Viacyte, Inc. | A biocompatible membrane composite |
| AU2020340622A1 (en) | 2019-09-05 | 2022-03-03 | Crispr Therapeutics Ag | Universal donor cells |
| US11118195B2 (en) | 2019-09-05 | 2021-09-14 | Crispr Therapeutics Ag | Universal donor cells |
| US12188051B2 (en) | 2020-05-27 | 2025-01-07 | The Regents Of The University Of Michigan | Compositions and methods for obtaining vascularized human intestinal organoid tissue, and related uses thereof |
| CN115843381A (zh) * | 2020-06-19 | 2023-03-24 | 富士胶片株式会社 | 信息处理装置、信息处理装置的工作方法、信息处理装置的工作程序 |
| CA3190604A1 (en) | 2020-08-15 | 2022-02-24 | Regeneron Pharmaceuticals, Inc. | Treatment of obesity in subjects having variant nucleic acid molecules encoding calcitonin receptor (calcr) |
| AU2021414405A1 (en) | 2020-12-31 | 2023-08-10 | Crispr Therapeutics Ag | Universal donor cells |
| WO2024151541A1 (en) | 2023-01-09 | 2024-07-18 | Sana Biotechnology, Inc. | Type-1 diabetes autoimmune mouse |
| WO2024243236A2 (en) | 2023-05-22 | 2024-11-28 | Sana Biotechnology, Inc. | Methods of delivery of islet cells and related methods |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004098490A2 (en) * | 2002-05-17 | 2004-11-18 | Mount Sinai School Of Medicine Of New York University | Mesoderm and definitive endoderm cell populations |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1234567A (en) * | 1915-09-14 | 1917-07-24 | Edward J Quigley | Soft collar. |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| US6165993A (en) | 1992-03-23 | 2000-12-26 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
| US7153684B1 (en) | 1992-10-08 | 2006-12-26 | Vanderbilt University | Pluripotential embryonic stem cells and methods of making same |
| US5690926A (en) | 1992-10-08 | 1997-11-25 | Vanderbilt University | Pluripotential embryonic cells and methods of making same |
| US5453357A (en) | 1992-10-08 | 1995-09-26 | Vanderbilt University | Pluripotential embryonic stem cells and methods of making same |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| US6015671A (en) | 1995-06-07 | 2000-01-18 | Indiana University Foundation | Myocardial grafts and cellular compositions |
| US6090592A (en) | 1994-08-03 | 2000-07-18 | Mosaic Technologies, Inc. | Method for performing amplification of nucleic acid on supports |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| JP3945846B2 (ja) | 1995-11-09 | 2007-07-18 | 武田薬品工業株式会社 | 膵臓機能改善剤 |
| JP2001517927A (ja) | 1996-02-28 | 2001-10-09 | バンダービルト ユニバーシティ | 胚幹細胞を作製する組成物および方法 |
| US6117635A (en) | 1996-07-16 | 2000-09-12 | Intergen Company | Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon |
| EP0938571B8 (en) | 1996-10-28 | 2008-07-02 | University of Lausanne | Method for the oligomerisation of peptides |
| EP0986635A4 (en) | 1997-01-10 | 2001-11-07 | Life Technologies Inc | SERUM SUBSTITUTE FOR EMBRYONIC STEM CELLS |
| US6090622A (en) | 1997-03-31 | 2000-07-18 | The Johns Hopkins School Of Medicine | Human embryonic pluripotent germ cells |
| US6331406B1 (en) * | 1997-03-31 | 2001-12-18 | The John Hopkins University School Of Medicine | Human enbryonic germ cell and methods of use |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| US5866366A (en) | 1997-07-01 | 1999-02-02 | Smithkline Beecham Corporation | gidB |
| ES2279580T3 (es) | 1997-09-15 | 2007-08-16 | Genetic Immunity, Llc | Composiciones para administrar genes a celulas de la piel que presentan antigenos. |
| EP1025204A4 (en) * | 1997-10-23 | 2001-02-28 | Geron Corp | Methods and materials for the growth of primate-derived primordial stem cells |
| US6117986A (en) | 1998-06-10 | 2000-09-12 | Intergen Company, L.P. | Pyrimidines linked to a quencher |
| US6921811B2 (en) * | 1998-09-22 | 2005-07-26 | Biosurface Engineering Technologies, Inc. | Bioactive coating composition and methods |
| US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
| DE19852800C1 (de) | 1998-11-16 | 2000-04-13 | Univ Albert Ludwigs Freiburg | Verfahren zur Herstellung von Antikörpern gegen ein Polypeptid, von dem die kodierende Nukleinsäure bekannt ist |
| GB9903804D0 (en) | 1999-02-20 | 1999-04-14 | Univ Sheffield | Pluripotential cells-2 |
| US6872389B1 (en) | 1999-07-08 | 2005-03-29 | Rhode Island Hospital | Liver stem cell |
| EP1248834A4 (en) | 2000-01-21 | 2004-03-17 | Univ Johns Hopkins | CELLS FROM HUMAN EMBRYOID BODIES |
| US7005252B1 (en) | 2000-03-09 | 2006-02-28 | Wisconsin Alumni Research Foundation | Serum free cultivation of primate embryonic stem cells |
| US7256042B2 (en) | 2000-04-27 | 2007-08-14 | Geron Corporation | Process for making hepatocytes from pluripotent stem cells |
| US6458589B1 (en) | 2000-04-27 | 2002-10-01 | Geron Corporation | Hepatocyte lineage cells derived from pluripotent stem cells |
| JP4426064B2 (ja) | 2000-05-31 | 2010-03-03 | 独立行政法人科学技術振興機構 | 脊椎動物の膵臓のインビトロ形成方法 |
| AU8617301A (en) * | 2000-08-01 | 2002-02-13 | Yissum Res Dev Co | Directed differentiation of embryonic cells |
| WO2002034880A2 (en) | 2000-10-23 | 2002-05-02 | University Of Kansas | Cadherin peptides for drug delivery and inhibition of tumor metastasis/invasion |
| US20020168763A1 (en) | 2000-11-30 | 2002-11-14 | Yan Wen Liang | Isolated homozygous stem cells, differentiated cells derived therefrom, and materials and methods for making and using same |
| EP1366148A2 (en) | 2001-01-24 | 2003-12-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES | Differentiation of stem cells to pancreatic endocrine cells |
| EP1393066A4 (en) | 2001-05-15 | 2006-01-25 | Rappaport Family Inst For Res | INSULIN-PRODUCING CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS |
| CA2451838A1 (en) | 2001-05-25 | 2002-12-05 | Cythera, Inc. | Stem cell differentiation |
| WO2002101385A1 (en) | 2001-06-13 | 2002-12-19 | Massachusetts Institute Of Technology | In vivo bioreactors |
| WO2002102982A2 (en) | 2001-06-14 | 2002-12-27 | Regents Of The University Of California | Hoxd3 compositions ad methods for improved wound healing |
| EP1298201A1 (en) | 2001-09-27 | 2003-04-02 | Cardion AG | Process for the production of cells exhibiting an islet-beta-cell-like state |
| WO2003046141A2 (en) * | 2001-11-26 | 2003-06-05 | Advanced Cell Technology, Inc. | Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells |
| GB2399823B (en) * | 2001-12-07 | 2006-02-15 | Geron Corp | Islet cells from primate pluripotent stem cells |
| US20030138949A1 (en) | 2001-12-12 | 2003-07-24 | Anil Bhushan | Methods for the regeneration of pancreatic islets and expansion of pancreatic endocrine cells |
| US20030162290A1 (en) | 2002-01-25 | 2003-08-28 | Kazutomo Inoue | Method for inducing differentiation of embryonic stem cells into functioning cells |
| WO2003089619A2 (en) * | 2002-04-19 | 2003-10-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Placental derived stem cells and uses thereof |
| US20060003446A1 (en) * | 2002-05-17 | 2006-01-05 | Gordon Keller | Mesoderm and definitive endoderm cell populations |
| CN1662643A (zh) | 2002-05-28 | 2005-08-31 | 贝克顿·迪金森公司 | 人腺泡细胞的扩增和转分化 |
| CN1668324A (zh) | 2002-05-28 | 2005-09-14 | 诺沃塞尔公司 | 用于胰岛素产生细胞的方法、组合物及生长与分化因子 |
| US20060040385A1 (en) | 2002-12-05 | 2006-02-23 | Technion Research & Development Foundation Ltd. | Cultured human pancreatic islets, and uses thereof |
| FR2849043B1 (fr) * | 2002-12-24 | 2005-07-08 | Gemac | Procede de fabrication d'un vecteur de molecules actives applicable dans le domaine de la diffusion de principes actifs et vecteur obtenu |
| CA2515108A1 (en) | 2003-02-07 | 2004-08-26 | Wisconsin Alumni Research Foundation | Directed genetic modifications of human stem cells |
| WO2004073633A2 (en) | 2003-02-14 | 2004-09-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for modulating the development of stem cells |
| WO2005045001A2 (en) | 2003-02-14 | 2005-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Insulin-producing cells derived from stem cells |
| US20030224411A1 (en) | 2003-03-13 | 2003-12-04 | Stanton Lawrence W. | Genes that are up- or down-regulated during differentiation of human embryonic stem cells |
| US20040229350A1 (en) | 2003-05-12 | 2004-11-18 | Nikolai Strelchenko | Morula derived embryonic stem cells |
| WO2004104184A1 (ja) * | 2003-05-20 | 2004-12-02 | Riken | 内胚葉系幹細胞の調製 |
| WO2005017131A2 (en) | 2003-08-14 | 2005-02-24 | THE GOUVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT F HEALTH AND HUMAN SERVICES | Methods for the differentiation of human stem cells |
| US7091082B2 (en) * | 2003-08-22 | 2006-08-15 | The Board Of Trustees Of The University Of Illinois | Semiconductor method and device |
| WO2005033294A2 (en) | 2003-09-30 | 2005-04-14 | Regents Of The University Of California | Methods for maintaining hepatocytes in culture and for differentiating embryonic stem cells along a hepatocyte lineage |
| US7985585B2 (en) * | 2004-07-09 | 2011-07-26 | Viacyte, Inc. | Preprimitive streak and mesendoderm cells |
| US8647873B2 (en) | 2004-04-27 | 2014-02-11 | Viacyte, Inc. | PDX1 expressing endoderm |
| KR101221302B1 (ko) | 2003-12-23 | 2013-01-11 | 비아싸이트, 인크. | 완전 내배엽 |
| US7625753B2 (en) | 2003-12-23 | 2009-12-01 | Cythera, Inc. | Expansion of definitive endoderm cells |
| US7541185B2 (en) | 2003-12-23 | 2009-06-02 | Cythera, Inc. | Methods for identifying factors for differentiating definitive endoderm |
| WO2007059007A2 (en) | 2005-11-14 | 2007-05-24 | Cythera, Inc. | Markers of definitive endoderm |
| WO2005097980A2 (en) | 2004-03-26 | 2005-10-20 | Geron Corporation | New protocols for making hepatocytes from embryonic stem cells |
| CA2555571C (en) | 2004-04-01 | 2012-10-16 | Wisconsin Alumni Research Foundation | Differentiation of stem cells to endoderm and pancreatic lineage |
| ES2751095T3 (es) | 2004-04-27 | 2020-03-30 | Viacyte Inc | Endodermo que expresa pdx1 |
| ES2754038T3 (es) | 2004-07-09 | 2020-04-15 | Viacyte Inc | Células mesendodérmicas y células de línea pre-primitiva |
| AU2005272078B2 (en) | 2004-07-09 | 2011-04-14 | Viacyte, Inc. | Methods for identifying factors for differentiating definitive endoderm |
| EP1791952A4 (en) | 2004-08-13 | 2008-06-11 | Univ Georgia Res Found | COMPOSITIONS AND METHODS OF SELF-RENEWAL AND DIFFERENTIATION IN HUMAN EMBRYONAL STEM CELLS |
| WO2006034873A1 (en) | 2004-09-29 | 2006-04-06 | Cellartis Ab | METHODS FOR THE GENERATION OF HEPATOCYTE-LIKE CELLS FROM HUMAN BLASTOCYST-DERIVED STEM (hBs) |
| JP2008528038A (ja) | 2005-01-31 | 2008-07-31 | エス セル インターナショナル ピーティーイー リミテッド | 胚性幹細胞の指示された分化及びその利用 |
| WO2007002210A2 (en) | 2005-06-20 | 2007-01-04 | Bresagen, Inc. | Embryonic stem cell culture compositions and methods of use thereof |
| SG169324A1 (en) | 2005-10-14 | 2011-03-30 | Univ Minnesota | Differentiation of non-embryonic stem cells to cells having a pancreatic phenotype |
| EP3584311A1 (en) | 2005-10-27 | 2019-12-25 | Viacyte, Inc. | Pdx-1 expressing dorsal and ventral foregut endoderm |
| GB0602063D0 (en) | 2006-02-02 | 2006-03-15 | Univ Manchester | Cell Culture |
| AU2007277364B2 (en) | 2006-07-26 | 2010-08-12 | Viacyte, Inc. | Methods of producing pancreatic hormones |
| WO2009154606A1 (en) * | 2008-06-03 | 2009-12-23 | Cythera, Inc. | Growth factors for production of definitive endoderm |
-
2004
- 2004-12-23 KR KR1020067012582A patent/KR101221302B1/ko not_active Expired - Lifetime
- 2004-12-23 MX MX2009009225A patent/MX2009009225A/es active IP Right Grant
- 2004-12-23 CN CN201410120990.2A patent/CN103898045B/zh not_active Expired - Lifetime
- 2004-12-23 US US10/584,338 patent/US7704738B2/en active Active
- 2004-12-23 NZ NZ547920A patent/NZ547920A/en not_active IP Right Cessation
- 2004-12-23 EP EP04815710.1A patent/EP1709159B1/en not_active Expired - Lifetime
- 2004-12-23 JP JP2006547496A patent/JP4819697B2/ja not_active Expired - Lifetime
- 2004-12-23 SG SG200809546-5A patent/SG149061A1/en unknown
- 2004-12-23 DK DK04815710.1T patent/DK1709159T3/da active
- 2004-12-23 DK DK13186231.0T patent/DK2722387T3/da active
- 2004-12-23 EP EP13186231.0A patent/EP2722387B1/en not_active Expired - Lifetime
- 2004-12-23 EA EA200601231A patent/EA200601231A1/ru unknown
- 2004-12-23 CN CN201410120976.2A patent/CN103898047B/zh not_active Expired - Lifetime
- 2004-12-23 WO PCT/US2004/043696 patent/WO2005063971A2/en not_active Ceased
- 2004-12-23 CA CA2807342A patent/CA2807342C/en not_active Expired - Lifetime
- 2004-12-23 AU AU2004309421A patent/AU2004309421B2/en not_active Expired
- 2004-12-23 MX MXPA06007252A patent/MXPA06007252A/es active IP Right Grant
- 2004-12-23 US US11/021,618 patent/US7510876B2/en not_active Expired - Lifetime
- 2004-12-23 CA CA2549605A patent/CA2549605C/en not_active Expired - Lifetime
-
2006
- 2006-06-15 IL IL176336A patent/IL176336A/en active IP Right Grant
-
2009
- 2009-03-30 US US12/414,482 patent/US8623645B2/en active Active
-
2010
- 2010-02-22 US US12/710,300 patent/US20100151568A1/en not_active Abandoned
-
2011
- 2011-04-06 AU AU2011201552A patent/AU2011201552B2/en not_active Expired
- 2011-08-01 JP JP2011168363A patent/JP5669688B2/ja not_active Expired - Lifetime
-
2013
- 2013-11-05 US US14/072,642 patent/US20140134727A1/en not_active Abandoned
-
2014
- 2014-09-12 JP JP2014186172A patent/JP6356021B2/ja not_active Expired - Lifetime
- 2014-10-21 HK HK14110480.0A patent/HK1197082A1/en unknown
- 2014-12-31 HK HK14113099.7A patent/HK1199741A1/xx unknown
- 2014-12-31 HK HK14113097.9A patent/HK1199740A1/xx unknown
-
2015
- 2015-06-01 JP JP2015111659A patent/JP2015163081A/ja active Pending
-
2016
- 2016-11-30 JP JP2016232292A patent/JP6574158B2/ja not_active Expired - Lifetime
-
2017
- 2017-02-13 US US15/431,634 patent/US10421942B2/en not_active Expired - Lifetime
-
2018
- 2018-07-09 JP JP2018130280A patent/JP2018171071A/ja active Pending
-
2019
- 2019-08-13 US US16/539,966 patent/US20190376028A1/en not_active Abandoned
-
2020
- 2020-02-27 JP JP2020032178A patent/JP7045407B2/ja not_active Expired - Lifetime
-
2021
- 2021-11-05 US US17/519,823 patent/US20220056405A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004098490A2 (en) * | 2002-05-17 | 2004-11-18 | Mount Sinai School Of Medicine Of New York University | Mesoderm and definitive endoderm cell populations |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7045407B2 (ja) | 胚体内胚葉 | |
| JP6709262B2 (ja) | Pdx1発現性内胚葉 | |
| ZA200605100B (en) | Definitive endoderm | |
| AU2015200780B2 (en) | Definitive endoderm | |
| AU2011204911A1 (en) | Definitive endoderm | |
| AU2013200203A1 (en) | Definitive endoderm |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070731 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20080314 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080321 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080314 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100623 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20100623 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20100716 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100727 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101026 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101102 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101119 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110127 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110128 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110301 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110601 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110608 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110701 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110708 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110801 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110823 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110901 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140909 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4819697 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |